Bausch + Lomb Reports Strong Q3 2026 Results with Growth Across All Business Segments
Bausch + Lomb (BLCO) reported robust third-quarter 2026 financial results, characterized by an 8% constant currency revenue increase to $1.375 billion. The company saw significant growth across its Vision Care, Pharmaceuticals, and Surgical segments, driven largely by high demand for dry eye treatments and premium intraocular lenses. Adjusted EBITDA rose 34% year-over-year to $325 million, reflecting improved operating leverage and disciplined execution. Key drivers included the rapid expansion of Miebo revenue (+42%) and a massive 75% surge in premium IOL revenue. The company also made significant progress on its balance sheet, reducing net leverage from 5.7x to 4.1x. While surgical equipment revenue saw an 11% decline due to strategic shifts toward consumable-driven placements, the overall outlook remains positive with raised full-year revenue guidance.
Topics: Debt Reduction EBITDA Expansion Free Cash Flow Revenue Growth Segment Performance